AU2021392655A1 - Methods and materials for treating t cell cancers - Google Patents

Methods and materials for treating t cell cancers Download PDF

Info

Publication number
AU2021392655A1
AU2021392655A1 AU2021392655A AU2021392655A AU2021392655A1 AU 2021392655 A1 AU2021392655 A1 AU 2021392655A1 AU 2021392655 A AU2021392655 A AU 2021392655A AU 2021392655 A AU2021392655 A AU 2021392655A AU 2021392655 A1 AU2021392655 A1 AU 2021392655A1
Authority
AU
Australia
Prior art keywords
polypeptide
seq
cell
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021392655A
Other languages
English (en)
Other versions
AU2021392655A9 (en
Inventor
Sarah DINAPOLI
Jacqueline DOUGLASS
Emily Han-Chung HSIUE
Michael S. HWANG
Kenneth W. Kinzler
Maximilian KONIG
Brian J. MOG
Nickolas Papadopoulos
Andrew M. PARDOLL
Suman PAUL
Alexander H. PEARLMAN
Bert Vogelstein
Shibin Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2021392655A1 publication Critical patent/AU2021392655A1/en
Publication of AU2021392655A9 publication Critical patent/AU2021392655A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021392655A 2020-12-01 2021-12-01 Methods and materials for treating t cell cancers Pending AU2021392655A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119753P 2020-12-01 2020-12-01
US63/119,753 2020-12-01
PCT/US2021/061453 WO2022119955A1 (en) 2020-12-01 2021-12-01 Methods and materials for treating t cell cancers

Publications (2)

Publication Number Publication Date
AU2021392655A1 true AU2021392655A1 (en) 2023-06-22
AU2021392655A9 AU2021392655A9 (en) 2024-05-02

Family

ID=79021888

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021392655A Pending AU2021392655A1 (en) 2020-12-01 2021-12-01 Methods and materials for treating t cell cancers

Country Status (7)

Country Link
US (1) US20240002541A1 (enExample)
EP (1) EP4255482A1 (enExample)
JP (1) JP2023551535A (enExample)
CN (1) CN116867519A (enExample)
AU (1) AU2021392655A1 (enExample)
CA (1) CA3203773A1 (enExample)
WO (1) WO2022119955A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
US20260193361A1 (en) * 2022-11-11 2026-07-09 Pasithea Therapeutics Corp. Anti-alpha5 integrin antibodies and uses thereof
IL326971A (en) * 2023-09-05 2026-05-01 Michele Pitaro Single-chain variable fragment and molecules derived therefrom that bind the trvb5-1 fragment of the β chain of the human T-cell receptor
WO2025247325A1 (en) * 2024-05-30 2025-12-04 Hanx Biopharmaceuticals, (Wuhan) Ltd. Antibody-drug conjugates targeting trbv12 and uses thereof
WO2026011103A1 (en) * 2024-07-03 2026-01-08 Yale University Tcr-vβeta specific therapeutic molecules and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
KR20180020202A (ko) * 2015-06-01 2018-02-27 메디진 이뮤노테라피스 게엠바하 T 세포 수용체 특이적 항체
EP3192810A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
US11807662B2 (en) * 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
WO2020010250A2 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
WO2020172598A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
SG11202109122SA (en) * 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof

Also Published As

Publication number Publication date
JP2023551535A (ja) 2023-12-08
US20240002541A1 (en) 2024-01-04
CA3203773A1 (en) 2022-06-09
EP4255482A1 (en) 2023-10-11
AU2021392655A9 (en) 2024-05-02
WO2022119955A1 (en) 2022-06-09
CN116867519A (zh) 2023-10-10

Similar Documents

Publication Publication Date Title
AU2023278069B2 (en) Chimeric antigen receptor T cells targeting the tumor microenvironment
AU2019218989B2 (en) Chimeric antigen receptors targeting the tumor microenvironment
JP7717439B2 (ja) 修飾されたｔ細胞及びその使用方法
JP7818348B2 (ja) キメラ抗原受容体を発現するｔ細胞
US20240002541A1 (en) Methods and materials for treating t cell cancers
KR20190101979A (ko) 합성 면역 수용체 및 이의 사용 방법
AU2018250336A1 (en) Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
JP2019510498A (ja) 癌を標的とするキメラ抗原受容体
TW201806619A (zh) 嵌合抗原受體及pd-1抑制劑之組合療法
CN112292140B (zh) 靶向cd37和cd19的嵌合抗原受体
CN110461363B (zh) 靶向cd37的嵌合抗原受体
JP2024540359A (ja) Ｔｅａｍを分泌する抗メソテリンｃａｒｔ細胞とその使用方法
CN111819186A (zh) 表达嵌合抗原受体的免疫细胞
US20230322923A1 (en) Methods and compositions relating to ex vivo culture and modulation of t cells
US20220347214A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
WO2022020720A9 (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
SREP Specification republished